SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Approves Roche’s Gazyva for Adult Kidney Disease

The FDA approved Gazyva/Gazyvaro for adults with primary membranous nephropathy.

Story updates

06:01:57 AM UTC
SquawkNews
Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
06:02:07 AM UTC
SquawkNews
The FDA approved Gazyva/Gazyvaro for adults with primary membranous nephropathy at risk of progression. In the phase III study, complete remission at week 104 was 36.1% versus 5.7% with tacrolimus; no prior-period comparison was provided.Material DetailsContext by AI AnalystThis is a new regulatory…

Related stories